A Phase II clinical trial of Cytokinetics’ investigational drug candidate, CK-3773274 (CK-274), has shown positive top-line data from first and second cohorts in hypertrophic cardiomyopathy (HCM) patients.
Data from the REDWOOD-HCM trial revealed statistically significant decreases in the average resting left ventricular outflow tract pressure gradient (LVOT-G) and the average post-Valsalva LVOT-G from baseline when treated with CK-274 for ten weeks.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Compared to placebo, most of the CK-274-treated participants reached the target treatment goal, determined as resting gradient and post-Valsalva gradient of less than 30mmHg and 50mmHg, respectively, at week ten.
LVOT-G reductions were observed in two weeks of starting the CK-274 treatment. These effects were maximised in two to six weeks of the dose titration initiation and maintained until the end of the ten-week treatment period.
The LVOT-G reductions were also reported to be dose-dependent and patients experienced higher decreases with increasing CK-274 doses.
CK-274 was generally well-tolerated during the trial with the occurrence of adverse events being similar between treatment groups. The drug candidate was not associated with any serious adverse events.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCytokinetics Research & Development executive vice-president Fady Malik said: “The combined data from Cohorts 1 and 2 in REDWOOD-HCM met our high expectations for this trial of CK-274 in patients with obstructive HCM, given the observed onset of response to initiation of treatment, magnitude and breadth of response, reversibility of LVEF decreases and favourable tolerability profile.”
CK-274 is an oral, small-molecule inhibitor of cardiac myosin intended to mitigate hypercontractility related to HCM.
A multi-centre, randomised, placebo-controlled, double-blind, dose-finding Phase II trial, REDWOOD-HCM assessed the drug in symptomatic obstructive HCM patients receiving background treatment.
Safety and tolerability of CK-274 were the primary objectives while secondary objectives were the concentration-response link between CK-274 and the resting and post-Valsalva LVOT-G, established using echocardiography over the treatment period.
The REDWOOD-HCM data inform dose selection and back the entry of CK-274 into a planned Phase III registrational trial set to commence before year-end.
In October 2020, Cytokinetics and its partners Amgen and Servier announced mixed results from the Phase III GALACTIC-HF trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction.
